Premium
Detection of Hepatitis B Virus DNA Directly in Human Serum by a Simplified Molecular Hybridization Test: Comparison to HBeAg/ Anti‐HBe Status in HBsAg Carriers
Author(s) -
Lieberman Harvey M.,
Labrecque Douglas R.,
Kew Michael C.,
Hadziyannis Stefanos J.,
Shafritz David A.
Publication year - 2007
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840030302
Subject(s) - hbeag , hepatocellular carcinoma , hbsag , hepatitis b virus , medicine , virology , hepatitis b , cirrhosis , hepadnaviridae , hepatitis , immunology , virus
A simple, direct molecular hybridization test was employed to detect hepatitis B virus (HBV) DNA sequences in human serum. In 61 HBsAg carriers, many with HBV‐related diseases (chronic persistent hepatitis, chronic active hepatitis, or posthepatitic cirrhosis), 28/28 (100%) who were HBeAg* and 16/32 (50%) who were anti‐HBe + had HBV DNA sequences in their serum. Among 22 South African black patients with hepatocellular carcinoma, 7 (32%) had detectable HBV DNA in their serum but at reduced levels when compared to HBsAg carriers without hepatocellular carcinoma, suggesting that viral replication is suppressed or inactive in many hepatocellular carcinoma patients. Hybridization analysis also distinguished carriers with high, moderate, or low amounts of HBV DNA in serum. Ten to 20% of HBsAg + /HBeAg + carriers showed high serum levels of HBV DNA but, surprisingly, a similar percentage of HBsAg + /anti‐HBe + carriers also showed relatively high serum levels of HBV DNA. Five patients who had undergone immunosuppression therapy and most of whom were on chronic hemodialysis had very high serum levels of HBV DNA, in the range observed during acute HBV infection. By epidemiologic analysis, two of these individuals were implicated in transmission of hepatitis to other hemodialysis patients, paramedical personnel, or intimate family contacts. Serum HBV DNA hybridization analysis identifies carriers with high serum levels of HBV irrespective of HBeAg/anti‐HBe status and may define individuals with potentially high risk of transmitting infection to their immediate contacts.